Cerezyme, Imiglucerase News

LONDON, UK , 11 May 2012 - Rare and niche diseases are being increasingly spotlighted by pharmaceutical and biotechnology corporations in the hope of developing initial treatments or improving upon existing therapies for these conditions, according to a new report released by GlobalData.

LONDON, UK , 8 May 2012 - On May 1, 2012, the FDA approved Protalix BioTherapeutic's Elelyso , a new enzyme replacement therapy that provides patients with Gaucher disease an alternative therapeutic option to Genzyme's Cerezyme , the current market leader and standard of care in Gaucher disease, and Shire's Vpriv .

Patients who are currently being treated with a stable dose of imiglucerase alfa can be switched to taliglucerase alfa and should initially receive the same dose of the Pfizer drug, according to the latter product's labeling.

Protalix Biotherapeutics , partnered with Pfizer , has just received FDA approval for their lead product candidate, ELELYSO , for the treatment of type I Gaucher disease.

Pfizer and its partner, Protalix BioTherapeutics, just got some good news from the Food and Drug Administration: Elelyso, a treatment for a rare genetic disorder called Gaucher disease, was approved.